View in EDS HTML Full Text PDF Full Text

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.

Saved in:
Bibliographic Details
Title: Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.
Authors: Fujiki, Shinya1 (AUTHOR), Iijima, Kenichi1 (AUTHOR), Okabe, Masaaki2 (AUTHOR), Niwano, Shinichi3 (AUTHOR), Tsujita, Kenichi4 (AUTHOR), Naito, Shigeto5 (AUTHOR), Ando, Kenji6 (AUTHOR), Kusano, Kengo7 (AUTHOR), Kato, Ritsushi8,9 (AUTHOR), Nitta, Junichi10 (AUTHOR), Miura, Tetsuji11 (AUTHOR), Mitsuhashi, Takeshi12 (AUTHOR), Kario, Kazuomi13 (AUTHOR), Kondo, Yusuke14 (AUTHOR), Ieda, Masaki15 (AUTHOR), Hagiwara, Nobuhisa16 (AUTHOR), Murohara, Toyoaki17 (AUTHOR), Takahashi, Kazuyoshi18 (AUTHOR), Tomita, Hirofumi19 (AUTHOR), Takeishi, Yasuchika20 (AUTHOR)
Source: Diabetes Therapy. Nov2020, Vol. 11 Issue 11, p2739-2755. 17p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18696953
DOI:10.1007/s13300-020-00924-9